Fulltext

How to cross immunogenetic hurdles to human embryonic stem cell transplantation

de Rham, Casimir ; Villard, Jean

In: Seminars in Immunopathology, 2011, vol. 33, no. 6, p. 525-534

Ajouter à la liste personnelle
    Titre
    • How to cross immunogenetic hurdles to human embryonic stem cell transplantation
    Auteur
    • de Rham, Casimir. Transplant Immunology Unit, Division of Immunology and Allergy and Division of Laboratory Medicine, Geneva University Hospital and Medical School, 4, rue Gabrielle-Perret-Gentil, 1211, Geneva 14, Switzerland
    • Villard, Jean. Transplant Immunology Unit, Division of Immunology and Allergy and Division of Laboratory Medicine, Geneva University Hospital and Medical School, 4, rue Gabrielle-Perret-Gentil, 1211, Geneva 14, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Seminars in Immunopathology, 2011, vol. 33, no. 6, p. 525-534. Springer-Verlag
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:319631
    Summary
    Implantation of human embryonic stem cells (hES), derived progenitors or mature cells derived from hES has great therapeutic potential for many diseases. If hES would come from genetically unrelated individuals, it would be probably rejected by the immune system of the recipient. Blood groups, MHC and minor antigens are the immunogenetic hurdles that have to be crossed for successful transplantation. Autologous transplantation with adult stem cells would be the best approach but several elements argue against this option. Classical immunosuppression, depleting antibody, induction of tolerance and stem cell banking are alternative methods that could be proposed to limit the risk of rejection